ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

peginterferon alfa-2b

Also written as “Peginterferon alfa-2b”, “peginterferon alfa-2b (SCH 54031)” and “PEG-Intron”.

Its studies are mostly in Hepatitis C, Chronic · Hepatitis C · Hepatitis B, Chronic · Melanoma · Hepatitis B, led by 4 companies.

Drug pagePeginterferon alfa-2b: every studyAll 139 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 15, 200552 company-led studies, 2 open or runningNext primary completion: May 31, 2029

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck450 open or runningphase 4since Nov 15, 2005Mar 29, 2000none ahead
Tanabe Pharmaits history only30 open or runningphase 3since Nov 2, 2011Feb 24, 2008none ahead
Xiamen Amoytop Biotechits history only32 open or runningphase 3since Apr 12, 2021Apr 12, 2021May 31, 2029NCT06707922
FGK Clinical Researchits history only10 open or runningphase 4since Jul 11, 2006Jul 11, 2006none ahead

Also a collaborator on its studies: Vertex Pharmaceuticals, Integrated Therapeutics Group, Johnson & Johnson and ViroPharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 28 studies since Mar 29, 2000.

  1. Mar 3, 2010Phase 1 study in Hepatitis C, ChronicNCT01081158 · 41 enrolled
  2. Sep 9, 2011Phase 1 study in Renal InsufficiencyNCT01432535 · 25 enrolled
  3. Feb 2, 2012Phase 1 study in Hepatitis C, ChronicNCT01547312
  4. May 1, 2012Phase 3 study in Hepatitis C, ChronicNCT01590225
  5. May 24, 2012Phase 4 study in Hepatitis C, ChronicNCT01606800 · 45 enrolled
  6. Jul 5, 2012Phase 1 study in MelanomaNCT01636960 · 9 enrolled
  7. Jul 11, 20122 phase 3 studiesNCT01641926, NCT01641666
  8. Aug 30, 2012Phase 1 study in Hepatitis C, ChronicNCT01678131 · 31 enrolled
  9. Nov 12, 2012Phase 4 study in Hepatitis BNCT01727271
  10. Sep 13, 2013Phase 3 study in Hepatitis C, ChronicNCT01945294 · 257 enrolled
  11. Mar 14, 2014Phase 2 study in Carcinoma, Renal CellNCT02089685 · 295 enrolled
  12. Jun 2, 2014Phase 2 study in MelanomaNCT02155322 · 33 enrolled
  13. May 15, 20183 phase 3 studiesNCT03537274, NCT03547154, NCT03552549
  14. May 31, 2018Phase 1 study in NeoplasmsNCT03554005 · 29 enrolled

TargetBeta

“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
peginterferon alfa-2aruleHoffmann-La Rochephase 4100
Interferon beta-1aruleBiogenphase 460

Studies

All 45 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03554005Neoplasms1CompletedMar 16, 200129
NCT03552549Melanoma3TerminatedFeb 19, 2001126
NCT03547154Leukemia, Myelogenous, Chronic, BCR-ABL Positive3TerminatedFeb 20, 2001344
NCT03537274Hepatitis C3CompletedJul 23, 19991,224
NCT02155322Melanoma2CompletedMar 21, 201633
NCT02089685Carcinoma, Renal Cell2CompletedApr 1, 2021295
NCT01945294Hepatitis C, Chronic3CompletedAug 5, 2015257
NCT01727271Hepatitis B4WithdrawnAug 20170
NCT01678131Hepatitis C, Chronic1CompletedAug 27, 201331
NCT01641926Hepatitis B, Chronic3TerminatedJan 21, 2016402
NCT01641666Hepatitis C, Chronic3WithdrawnSep 20160
NCT01636960Melanoma1TerminatedMar 26, 20149
NCT01606800Hepatitis C, Chronic4TerminatedJan 26, 201545
NCT01590225Hepatitis C, Chronic3WithdrawnAug 18, 20210
NCT01547312Hepatitis C, Chronic1WithdrawnNov 20120
NCT01432535Renal Insufficiency1CompletedAug 201225
NCT01081158Hepatitis C, Chronic1CompletedAug 200841
NCT00811967Hepatitis C, Chronic3TerminatedMay 200650
NCT00787371Hepatitis C, Chronic2CompletedJul 200669
NCT00761735Hepatitis C, Chronic3CompletedJan 201394
NCT00759109Carcinoma, Hepatocellular3CompletedNov 2009150
NCT00724620Hepatitis C, Chronic4CompletedFeb 2008103
NCT00687544Hepatitis C, Chronic4TerminatedSep 200811
NCT00687219Hepatitis C, Chronic3CompletedOct 2010102
NCT00686881Hepatitis C, Chronic3TerminatedFeb 2011261
NCT00686790Hepatitis D, Chronic3CompletedMay 200968
NCT00686777Hepatitis C, Chronic4CompletedDec 201075
NCT00686517Hepatitis C3CompletedDec 2010130
NCT00536263Hepatitis B, Chronic3CompletedNov 2009671
NCT00493805Hepatitis C, Chronic4TerminatedOct 200959
NCT00457418Melanoma1CompletedMay 27, 200832
NCT00441584Hepatitis C, Chronic3TerminatedJun 2008117
NCT00423800Hepatitis C, Chronic3TerminatedOct 200956
NCT00381017Hepatitis C3Withdrawn0
NCT00378599Hepatitis C, Chronic3CompletedJul 2009125
NCT00371761Hepatitis B3CompletedFeb 200925
NCT00302081Hepatitis C, Chronic3CompletedApr 2008696
NCT00265395Hepatitis C, Chronic3CompletedMay 20081,428
NCT00255034Hepatitis C, Chronic4TerminatedJun 2008146
NCT00237484Hepatitis C, Chronic3CompletedJun 30, 201189
NCT00104052Hepatitis C, Chronic3CompletedNov 2007107
NCT00049842Hepatitis C, Chronic3CompletedOct 2009540
NCT00048724Hepatitis C, Chronic3CompletedApr 2008631
NCT00035360HIV Infections3CompletedOct 200349
NCT00005012HIV Infections · United States, Puerto Rico2Completed250

How it is read

Names in the registry

  • “Peginterferon alfa-2b”, 10 entries
  • “peginterferon alfa-2b (SCH 54031)”, 5 entries
  • “PEG-Intron”, 4 entries
  • “PegIntron (peginterferon alfa-2b)”, 4 entries
  • “Peginterferon alfa-2b injection”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.